Johnson & Johnson - JNJ Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $227.55
  • Forecasted Upside: 1.36%
  • Number of Analysts: 26
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 16 Buy Ratings
  • 1 Strong Buy Ratings
$224.50
▲ +3.009 (1.36%)

This chart shows the closing price for JNJ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Johnson & Johnson Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JNJ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JNJ

Analyst Price Target is $227.55
▲ +1.36% Upside Potential
This price target is based on 26 analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $227.55, with a high forecast of $265.00 and a low forecast of $190.00. The average price target represents a 1.36% upside from the last price of $224.50.

This chart shows the closing price for JNJ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 26 polled investment analysts is to moderate buy stock in Johnson & Johnson. This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/5/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/3/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
2/1/2025
  • 2 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/2/2025
  • 2 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 0 sell ratings
7/31/2025
  • 2 strong buy ratings
  • 14 buy ratings
  • 8 hold ratings
  • 0 sell ratings
10/29/2025
  • 3 strong buy ratings
  • 14 buy ratings
  • 8 hold ratings
  • 0 sell ratings
12/28/2025
  • 1 strong buy ratings
  • 16 buy ratings
  • 9 hold ratings
  • 0 sell ratings
1/27/2026

Latest Recommendations

  • 1 strong buy ratings
  • 16 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/27/2026Loop CapitalSet Target$220.00
1/23/2026GuggenheimBoost TargetBuy ➝ Buy$227.00 ➝ $240.00
1/23/2026ArgusBoost Target$210.00 ➝ $240.00
1/23/2026Sanford C. BernsteinBoost TargetMarket Perform ➝ Market Perform$208.00 ➝ $225.00
1/22/2026ScotiabankReiterated RatingOutperform ➝ Outperform
1/22/2026TD CowenBoost TargetBuy ➝ Buy$222.00 ➝ $250.00
1/22/2026Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$197.00 ➝ $200.00
1/22/2026The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$250.00
1/22/2026CitigroupBoost TargetBuy ➝ Buy$232.00 ➝ $250.00
1/22/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$230.00 ➝ $240.00
1/22/2026Leerink PartnersBoost TargetMarket Perform ➝ Market Perform$201.00 ➝ $232.00
1/22/2026Bank of AmericaBoost TargetNeutral ➝ Neutral$220.00 ➝ $221.00
1/22/2026ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$230.00 ➝ $265.00
1/22/2026Stifel NicolausBoost TargetHold ➝ Hold$205.00 ➝ $220.00
1/16/2026Freedom CapitalDowngradeStrong-Buy ➝ Hold
1/9/2026Sanford C. BernsteinBoost TargetMarket Perform ➝ Market Perform$193.00 ➝ $208.00
1/5/2026UBS GroupReiterated RatingBuy ➝ Buy
1/5/2026Wolfe ResearchBoost TargetOutperform ➝ Outperform$225.00 ➝ $240.00
12/30/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$197.00 ➝ $217.00
12/18/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$213.00 ➝ $240.00
12/17/2025Royal Bank Of CanadaSet Target$240.00
12/15/2025Bank of AmericaBoost TargetNeutral ➝ Neutral$204.00 ➝ $220.00
12/12/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$190.00 ➝ $197.00
12/12/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$212.00 ➝ $230.00
12/11/2025BMO Capital MarketsReiterated RatingOutperform ➝ Outperform
12/11/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$209.00 ➝ $230.00
12/11/2025CitigroupBoost TargetBuy ➝ Buy$215.00 ➝ $232.00
12/10/2025HSBCReiterated RatingBuy ➝ Buy$240.00
12/5/2025GuggenheimBoost TargetBuy ➝ Buy$206.00 ➝ $227.00
12/2/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$176.00 ➝ $197.00
11/13/2025ScotiabankInitiated CoverageSector Outperform$230.00
11/12/2025ScotiabankUpgradeStrong-Buy
10/31/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
10/22/2025Johnson RiceSet TargetOutperform ➝ Hold$190.00
10/22/2025Loop CapitalSet Target$190.00
10/20/2025Daiwa Capital MarketsUpgradeNeutral ➝ Outperform$203.00
10/16/2025HSBCBoost TargetBuy ➝ Buy$210.00 ➝ $215.00
10/15/2025ArgusSet Target$210.00
10/15/2025Raymond James FinancialBoost TargetOutperform ➝ Outperform$174.00 ➝ $209.00
10/15/2025Morgan StanleySet Target$190.00
10/15/2025Stifel NicolausBoost TargetHold ➝ Hold$165.00 ➝ $190.00
10/15/2025CitigroupBoost TargetBuy ➝ Buy$213.00 ➝ $215.00
10/15/2025Bank of AmericaBoost TargetNeutral ➝ Neutral$198.00 ➝ $204.00
10/14/2025TD CowenReiterated RatingBuy ➝ Buy
10/14/2025UBS GroupBoost TargetBuy ➝ Buy$190.00 ➝ $214.00
10/10/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$209.00
10/10/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$176.00 ➝ $178.00
10/9/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$186.00 ➝ $212.00
10/8/2025Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
10/7/2025CitigroupBoost TargetBuy ➝ Buy$200.00 ➝ $213.00
10/6/2025Sanford C. BernsteinBoost TargetMarket Perform ➝ Market Perform$172.00 ➝ $193.00
10/3/2025UBS GroupSet Target$198.00
10/3/2025Wells Fargo & CompanySet TargetEqual Weight ➝ Overweight$170.00 ➝ $212.00
10/3/2025Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$170.00 ➝ $212.00
10/3/2025Bank of AmericaBoost TargetNeutral ➝ Neutral$175.00 ➝ $198.00
9/30/2025HSBCBoost Target$188.00 ➝ $210.00
9/27/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
9/23/2025GuggenheimUpgradeNeutral ➝ Buy$167.00 ➝ $206.00
9/19/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$185.00 ➝ $186.00
9/16/2025JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$185.00 ➝ $200.00
8/21/2025CitigroupBoost TargetBuy ➝ Buy$185.00 ➝ $200.00
7/23/2025Erste Group BankUpgradeHold ➝ Buy
7/17/2025Piper SandlerReiterated RatingOverweight ➝ Overweight
7/17/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$165.00 ➝ $176.00
7/17/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$181.00 ➝ $185.00
7/17/2025UBS GroupBoost TargetBuy ➝ Buy$180.00 ➝ $190.00
7/17/2025GuggenheimReiterated RatingNeutral ➝ Neutral$164.00 ➝ $167.00
7/17/2025Bank of AmericaBoost TargetNeutral ➝ Neutral$161.00 ➝ $175.00
7/17/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$171.00 ➝ $176.00
7/10/2025Morgan StanleyReiterated RatingUnderperform ➝ Underperform
7/10/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$169.00 ➝ $171.00
6/5/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$181.00
5/13/2025Leerink PartnersDowngradeOutperform ➝ Market Perform$169.00 ➝ $153.00
4/24/2025BenchmarkUpgradeStrong-Buy
4/17/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.00
4/16/2025Sanford C. BernsteinReiterated RatingMarket Perform ➝ Market Perform
4/16/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
4/16/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.00
4/14/2025Raymond James FinancialLower TargetOutperform ➝ Outperform$165.00 ➝ $162.00
4/10/2025Bank of AmericaLower TargetNeutral ➝ Neutral$171.00 ➝ $159.00
4/9/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$163.00 ➝ $164.00
4/9/2025The Goldman Sachs GroupUpgradeNeutral ➝ Buy$157.00 ➝ $172.00
4/2/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
4/2/2025GuggenheimReiterated RatingNeutral ➝ Neutral
3/10/2025GuggenheimReiterated RatingNeutral ➝ Neutral
3/5/2025Bank of AmericaBoost TargetNeutral ➝ Neutral$159.00 ➝ $171.00
2/19/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
2/3/2025GuggenheimBoost TargetNeutral ➝ Neutral$162.00 ➝ $166.00
1/28/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$159.00 ➝ $166.00
1/24/2025ArgusUpgradeStrong-Buy
1/23/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
1/23/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$175.00 ➝ $163.00
1/23/2025Leerink PartnersLower TargetOutperform ➝ Outperform$182.00 ➝ $169.00
1/23/2025Stifel NicolausLower TargetHold ➝ Hold$170.00 ➝ $155.00
1/23/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$166.00 ➝ $152.00
1/23/2025Raymond James FinancialLower TargetOutperform ➝ Outperform$170.00 ➝ $165.00
1/23/2025Bank of AmericaLower TargetNeutral ➝ Neutral$160.00 ➝ $159.00
1/21/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$160.00 ➝ $159.00
1/17/2025Bank of AmericaLower TargetNeutral ➝ Neutral$166.00 ➝ $160.00
12/11/2024CitigroupLower TargetBuy ➝ Buy$185.00 ➝ $175.00
12/10/2024Bank of AmericaReiterated RatingNeutral$166.00
11/15/2024Wolfe ResearchInitiated CoverageOutperform$190.00
11/6/2024GuggenheimBoost TargetNeutral ➝ Neutral$156.00 ➝ $162.00
10/16/2024CitigroupBoost TargetBuy ➝ Buy$180.00 ➝ $185.00
10/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
10/16/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$163.00 ➝ $166.00
10/16/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$178.00 ➝ $181.00
10/16/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$169.00 ➝ $175.00
10/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
10/8/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$175.00 ➝ $178.00
9/30/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
9/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
9/20/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
9/3/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
7/30/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
7/30/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
7/23/2024Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$160.00 ➝ $150.00
7/19/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$160.00 ➝ $155.00
7/18/2024Sanford C. BernsteinBoost Target$161.00 ➝ $171.00
7/18/2024TD SecuritiesLower Target$195.00 ➝ $185.00
7/18/2024TD CowenLower TargetBuy ➝ Buy$195.00 ➝ $185.00
7/18/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
7/18/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$167.00 ➝ $169.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00
6/17/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
6/4/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
5/30/2024The Goldman Sachs GroupInitiated CoverageNeutral$160.00
5/22/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$175.00
5/16/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$175.00
5/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
4/18/2024HSBCUpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024Bank of AmericaLower TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
3/13/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
2/28/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$181.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
2/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
1/24/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$170.00 ➝ $169.00
1/24/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$181.00
1/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
1/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
1/3/2024Raymond James FinancialBoost TargetOutperform ➝ Outperform$172.00 ➝ $175.00
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
12/13/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$170.00 ➝ $163.00
12/1/2023Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$178.00
12/1/2023UBS GroupUpgradeNeutral ➝ Buy$167.00 ➝ $180.00
11/17/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
10/18/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$174.00 ➝ $171.00
10/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
10/18/2023Raymond James FinancialLower TargetOutperform ➝ Outperform$179.00 ➝ $172.00
10/12/2023BarclaysBoost TargetEqual Weight ➝ Equal Weight$158.00 ➝ $162.00
10/11/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$172.00 ➝ $174.00
10/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
10/4/2023Royal Bank Of CanadaInitiated CoverageOutperform$178.00
10/2/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
9/8/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$175.00 ➝ $158.00
9/6/2023HSBCInitiated CoverageHold$175.00
9/5/2023Raymond James FinancialLower TargetOutperform ➝ Outperform$184.00 ➝ $179.00
8/31/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$187.00 ➝ $172.00
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
8/31/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$195.00 ➝ $186.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
8/4/2023Atlantic SecuritiesBoost TargetNeutral ➝ Neutral$167.00 ➝ $170.00
7/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00
7/24/2023BarclaysBoost TargetEqual Weight$171.00 ➝ $175.00
7/24/2023Raymond James FinancialBoost TargetOutperform$181.00 ➝ $184.00
7/21/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$187.00
7/21/2023JPMorgan Chase & Co.Boost TargetNeutral$175.00 ➝ $180.00
7/21/2023Stifel NicolausBoost Target$165.00 ➝ $175.00
7/21/2023Credit Suisse GroupBoost TargetNeutral$170.00 ➝ $175.00
5/30/2023CitigroupInitiated CoverageBuy$185.00
5/5/2023Credit Suisse GroupBoost Target$168.00 ➝ $170.00
4/19/2023Atlantic SecuritiesLower TargetNeutral$168.00 ➝ $167.00
4/19/2023Morgan StanleyBoost TargetEqual Weight$179.00 ➝ $183.00
4/19/2023Raymond James FinancialLower TargetOutperform$185.00 ➝ $181.00
4/10/2023Morgan StanleyLower TargetEqual Weight$180.00 ➝ $179.00
3/28/2023UBS GroupInitiated CoverageNeutral$164.00
2/28/2023GuggenheimInitiated CoverageNeutral$161.00
2/6/2023Piper SandlerLower Target$55.00 ➝ $52.00
2/1/2023Cantor FitzgeraldReiterated RatingOverweight$215.00
1/25/2023Atlantic SecuritiesBoost TargetNeutral$160.00 ➝ $168.00
1/25/2023Morgan StanleyBoost TargetEqual Weight$176.00 ➝ $180.00
1/20/2023Leerink PartnersLower TargetOutperform$194.00 ➝ $186.00
12/12/2022CitigroupBoost TargetBuy$198.00 ➝ $205.00
12/6/2022Morgan StanleyLower TargetEqual Weight$178.00 ➝ $176.00
12/1/2022Morgan StanleyBoost Target$170.00 ➝ $178.00
11/17/2022Credit Suisse GroupInitiated CoverageNeutral$170.00
10/19/2022Atlantic SecuritiesLower TargetNeutral$165.00 ➝ $160.00
10/19/2022Raymond James FinancialLower TargetOutperform$192.00 ➝ $185.00
10/19/2022Morgan StanleyLower TargetEqual Weight$174.00 ➝ $170.00
10/19/2022Sanford C. BernsteinLower Target$194.00 ➝ $190.00
10/17/2022BarclaysInitiated CoverageEqual Weight$175.00
10/14/2022Bank of AmericaLower TargetNeutral$185.00 ➝ $178.00
10/12/2022Morgan StanleyBoost TargetEqual Weight$173.00 ➝ $174.00
10/5/2022CitigroupLower Target$201.00 ➝ $198.00
9/12/2022Morgan StanleyLower TargetEqual Weight$174.00 ➝ $173.00
7/21/2022UBS GroupLower Target$185.00 ➝ $180.00
7/20/2022Leerink PartnersLower Target$200.00 ➝ $194.00
7/20/2022CitigroupLower Target$205.00 ➝ $201.00
7/13/2022Wells Fargo & CompanyBoost TargetOverweight$190.00 ➝ $195.00
7/8/2022Morgan StanleyBoost TargetEqual Weight$173.00 ➝ $174.00
6/22/2022Daiwa Capital MarketsInitiated CoverageOutperform
5/17/2022CitigroupLower Target$210.00 ➝ $205.00
4/20/2022Raymond James FinancialBoost TargetOutperform$195.00 ➝ $196.00
4/20/2022Credit Suisse GroupBoost TargetOutperform$200.00 ➝ $205.00
4/20/2022CitigroupBoost TargetBuy$203.00 ➝ $210.00
4/14/2022Raymond James FinancialBoost TargetOutperform$185.00 ➝ $195.00
4/12/2022The Goldman Sachs GroupBoost TargetNeutral$163.00 ➝ $181.00
4/6/2022Morgan StanleyLower TargetEqual Weight$175.00 ➝ $173.00
3/16/2022Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$180.00 ➝ $183.00
3/2/2022Bank of AmericaInitiated CoverageNeutral ➝ Neutral
1/26/2022Raymond James FinancialBoost Target$178.00 ➝ $185.00
1/24/2022Morgan StanleyLower TargetEqual Weight$187.00 ➝ $175.00
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$161.00
12/15/2021CitigroupReiterated RatingBuy ➝ Buy$192.00 ➝ $195.00
10/20/2021Raymond James FinancialLower TargetOutperform$183.00 ➝ $178.00
10/7/2021Wells Fargo & CompanyReiterated RatingBuy
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$187.00
7/29/2021Leerink PartnersReiterated RatingBuy
7/21/2021Leerink PartnersReiterated RatingOutperform
6/7/2021Credit Suisse GroupSet TargetBuy$193.00
6/1/2021Credit Suisse GroupSet TargetBuy$193.00
5/28/2021Morgan StanleyInitiated CoverageOverweight$187.00
1/27/2021JPMorgan Chase & Co.Boost TargetNeutral$157.00 ➝ $175.00
1/27/2021Credit Suisse GroupBoost TargetOutperform$168.00 ➝ $193.00
1/27/2021Raymond James FinancialBoost TargetOutperform$158.00 ➝ $183.00
1/27/2021TD CowenBoost TargetOutperform$170.00 ➝ $195.00
1/27/2021Morgan StanleyBoost TargetOverweight$178.00 ➝ $187.00
1/27/2021Leerink PartnersBoost TargetOutperform$180.00 ➝ $200.00
1/27/2021Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$175.00 ➝ $190.00
(Data available from 1/27/2021 forward)

News Sentiment Rating

1.08 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/30/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2025
  • 87 very positive mentions
  • 24 positive mentions
  • 10 negative mentions
  • 5 very negative mentions
12/28/2025
  • 198 very positive mentions
  • 86 positive mentions
  • 17 negative mentions
  • 3 very negative mentions
1/27/2026

Current Sentiment

  • 198 very positive mentions
  • 86 positive mentions
  • 17 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Johnson & Johnson logo
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Read More

Today's Range

Now: $224.50
Low: $220.70
High: $225.50

50 Day Range

MA: $208.79
Low: $199.99
High: $221.54

52 Week Range

Now: $224.50
Low: $141.50
High: $225.50

Volume

8,153,925 shs

Average Volume

9,509,127 shs

Market Capitalization

$540.88 billion

P/E Ratio

20.32

Dividend Yield

2.36%

Beta

0.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Johnson & Johnson?

The following Wall Street sell-side analysts have issued research reports on Johnson & Johnson in the last twelve months: Argus, Bank of America Corporation, Barclays PLC, Benchmark Co., BMO Capital Markets, Citigroup Inc., Daiwa Capital Markets, Erste Group Bank AG, Freedom Capital, Guggenheim, HSBC Holdings plc, Johnson Rice, JPMorgan Chase & Co., Leerink Partners, Loop Capital, Morgan Stanley, Piper Sandler, Raymond James Financial, Inc., Royal Bank Of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for JNJ.

What is the current price target for Johnson & Johnson?

0 Wall Street analysts have set twelve-month price targets for Johnson & Johnson in the last year. Their average twelve-month price target is $226.18, suggesting a possible upside of 0.5%. Scotiabank has the highest price target set, predicting JNJ will reach $265.00 in the next twelve months. Johnson Rice has the lowest price target set, forecasting a price of $190.00 for Johnson & Johnson in the next year.
View the latest price targets for JNJ.

What is the current consensus analyst rating for Johnson & Johnson?

Johnson & Johnson currently has 9 hold ratings, 16 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JNJ.

What other companies compete with Johnson & Johnson?

Other companies that are similar to Johnson & Johnson include Moderna, Novavax, AbbVie, Berkshire Hathaway and Kenvue. Learn More about companies similar to Johnson & Johnson.

How do I contact Johnson & Johnson's investor relations team?

Johnson & Johnson's physical mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company's listed phone number is (732) 524-0400 and its investor relations email address is [email protected]. The official website for Johnson & Johnson is www.jnj.com. Learn More about contacing Johnson & Johnson investor relations.